医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Nautilus, Inc. Expands Global Footprint in Europe, Australia and New Zealand

2016年01月20日 PM05:00
このエントリーをはてなブックマークに追加


 

VANCOUVER, Wash.

January 20, 2016 — Nautilus, Inc. (NYSE: NLS), a leader in innovative fitness equipment, today announced availability of the Bowflex Max Trainer® and Schwinn® Airdyne® AD 8 Total Fitness Bike in key international markets including Europe, Australia and New Zealand.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160120005335/en/

The Bowflex Max Trainer® optimizes cardio performance with a 14-minute interval workout. (Photo: Bus ...

The Bowflex Max Trainer® optimizes cardio performance with a 14-minute interval workout. (Photo: Business Wire)

“We continually pursue opportunities to make our innovative products accessible to the international marketplace,” said Jeff Collins, Vice President, General Manager – Retail, Nautilus, Inc. “Given strong interest from our global partners, along with the success we have experienced in the U.S. already, we are confident these products will be well received by customers in other markets around the world.”

As a result of securing partnerships with leading distributors, the Bowflex Max Trainer® and Schwinn® Airdyne® AD 8 will now be available in more than 15 countries.

Current partners for the Bowflex Max Trainer® include: Brand Developers in Australia; Trisport in Austria, Germany and Switzerland; Fitness Superstore for the U.K.; and Elite Fitness for New Zealand.

Current partners for the Schwinn Airdyne AD 8 include: The Fitness Generation in Australia; Sport-Tiedje for Austria and Germany; Elite Fitness for New Zealand and Fitness Superstore for the U.K.

The Bowflex Max Trainer® and Schwinn® Airdyne® AD 8 will also be previewed and demonstrated at the upcoming ISPO Munich, one of the largest sporting good expositions in the world, in the Nautilus, Inc. booth: Hall B4, Booth 428.

Bowflex Max Trainer®: Reinventing the Cardio Machine

The Bowflex Max Trainer® is an all-in-one cardio machine that combines the power of an elliptical and stair stepper to create a one-of-a-kind full body workout that delivers results in 14 minutes.

Bowflex Max Trainer® burns up to 2.5 times the calories of other exercise equipment, and engages the upper body 80 percent more than a traditional elliptical. Its sleek design enables full-body movement while remaining easier on the joints.

Bowflex Max Trainer® also provides users the ability to track their workouts with the free Bowflex Max Trainer® app that wirelessly transfers all workout data via Bluetooth® Smart technology. It tracks every detail — from time on the machine to calories burned — and automatically syncs workout data with Apple Health, Google Fit, as well as MyFitnessPal.

Its space-saving, compact design makes it ideal for workouts even if space is a limitation at home.

Bowflex Max Trainer® has also earned a number of global design awards, including the prestigious Red Dot Design Award and International Design Award (IDA).

Website: http://www.nautilusinternational.com/international-site-us/products/maxtrainer.jsp

Schwinn® Airdyne® AD 8 Total Fitness Bike: Revolutionizing the Stationary Bike

The new Schwinn® Airdyne® AD 8 Total Fitness Bike leverages the iconic Schwinn Airdyne Technology™ — its legacy built around the power of unlimited wind resistance — and takes the technology to the next level. From the performance engineered, perimeter-weighted flywheel for smooth startup and cycling, to the proven strength of the splined solid steel cranks that deliver more power to the pedals, to the moisture repellent double coated steel body construction, the Schwinn® Airdyne® AD 8 is designed to withstand the rigors of high intensity training by the most intense athletes.

The Schwinn® Airdyne® AD 8’s commercial-grade components are built to support multi-user, high workload environments — ranging from the local CrossFit®-affiliated gym to rehabilitation facilities — while the bike’s compact design also makes it ideal for the ultimate at-home workout experience.

The bike features a revolutionary multi-position handle, which offers users the flexibility to place hands either vertically or horizontally. The anti-slip foot platforms provide a more robust push off to leverage more power from every workout. Equipped with an oversize padded seat for ultimate comfort, a universal rail and clamp system, also gives users the flexibility to add a custom seat.

The Schwinn® Airdyne® AD 8 allows users to seamlessly and simply tailor the level of intensity — the more effort given, the more resistance that is delivered through the bike’s smooth, quiet direct drive belt system. In addition, Schwinn Airdyne Technology™ blends seamlessly with custom interval training programs to offer users of all levels uniquely challenging workouts with metrics like watts, calories, time, and distance.

Website: http://www.nautilusinternational.com/international-site-us/products

About Nautilus, Inc. Headquartered in Vancouver, Wash., Nautilus, Inc. (NYSE: NLS) is a global fitness solutions company that believes everyone deserves a fit and healthy life. With a brand portfolio including Bowflex®, Nautilus®, Octane Fitness®, Schwinn® and Universal®, Nautilus, Inc. develops innovative products to support healthy living through direct and retail channels as well as in commercial channels with Octane Fitness® products.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160120005335/en/

CONTACT

Investor Relations Contact:
ICR, LLC
John Mills, (646)
277-1254
or
Media Contacts:
Nautilus, Inc.
Erin
Griffin, +1-360-859-5863
egriffin@nautilus.com
or
The
Hoffman Agency
Kali Bean, +1-503-580-4645
kbean@hoffman.com

同じカテゴリーの記事 

  • EMS Kegel Trainer BODYDOCTOR Opens New Era of Health Care Solutions in Global Femcare Market
  • EMSケーゲルトレーナー BODYDOCTOR、Femcareのグローバル市場でK-HEALTH CAREに注目が集まる
  • InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
  • METIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長
  • Poxel to Report Its 2023 Annual Results by the End of April 2024